Drugs / ABBV-623
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04804254 | Apr 2021 → Jan 2023 | B-cell neoplasm | AbbVie | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-623 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04804254 ↗ |
| Route | Oral | “Participants in the combination expansion treatment arms will receive oral tablets of ABBV-623 and/or ABBV-992 once daily for 24 months.” NCT04804254 ↗ |